Compare Davita Inc (DVA) vs Gogoro Inc (GGR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Gogoro Inc — how do they compare? Davita Inc trades at $230.51 (market cap $14.92B), while Gogoro Inc trades at $3.93 (market cap $76.98M). The key difference: Davita Inc is far larger — about 193.8× Gogoro Inc's market cap, and Davita Inc is trading nearer its 52-week high, Gogoro Inc nearer its low. Which is the better fit depends on your goals.
| DVA | GGR | |
|---|---|---|
Market Cap | $14.92B | $76.98M |
Sector | Health | Technology |
52-Week High | $235.71 | $7.89 |
52-Week Low | $103.87 | $2.74 |
Enterprise Value | $27.47B | $379.42M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
GGR trades at $3.88, up 0.78% on the day, while showing bearish technical signals with a negative net income margin of -24.68% and ROE of -50.38% for 2025. The company reported revenue of $281.48M but a net loss of $79.97M, though cash flow from operations improved to $35.90M. Recent news highlights a private placement and Q1 2026 results emphasizing margin improvement and growth plans.
Outlook remains challenged by persistent losses and negative profitability metrics, offset by operational discipline and subscriber growth. Key risks include execution on profitability, competitive pressures, and cash flow sustainability. Analysts are neutral with 100% hold ratings, reflecting cautious optimism amid fundamental headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Gogoro Inc
Gogoro is a global technology leader in battery-swapping ecosystems for electric two-wheelers. It provides smart, sustainable urban mobility solutions and manages an extensive network of battery stations.
Read more on GGR →
